| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| HLA-B*0702 & B2M & HPV16 E7 (KPTLKEYVL) | Biotinylated Human HLA-B*07:02&B2M&HPV16 E7 (KPTLKEYVL) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug |   | |||
| HLA-B*0702 & B2M & HPV16 E7 (KPTLKEYVL) | Biotinylated Human HLA-B*07:02&B2M&HPV16 E7 (KPTLKEYVL) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms | Details |
| SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
| GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
| NM1F | NM1F; TGI-2 | Phase 1 Clinical | Hefei TG ImmunoPharma Co Ltd | Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
| SHR-2002 | SHR-2002 | Phase 1 Clinical | Neoplasms | Details | |
| JS-009 | JS009; TAB009; JS-009 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
| PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
